Changes in biosimilar knowledge among European Crohn's Colitis Organization [ECCO] members: An updated survey

Journal of Crohn's and Colitis

Volumn 10, Issue 11, 2016, Pages 1362-1365

  Danese, Silvio ^a,b   Fiorino, Gionata ^a   Michetti, Pierre ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

^c Gastro Entérologie la Source Beaulieu   (Switzerland)

Author keywords

Biosimilars; Inflammatory bowel disease

Indexed keywords

BIOSIMILAR AGENT; GASTROINTESTINAL AGENT;

ARTICLE; CLINICAL PRACTICE; COMPARATIVE STUDY; COST; CROHN DISEASE; DRUG SURVEILLANCE PROGRAM; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; IMMUNOGENICITY; MEDICAL EDUCATION; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; ATTITUDE TO HEALTH; DIET THERAPY; EUROPE; INFLAMMATORY BOWEL DISEASE; MEDICAL SOCIETY; QUESTIONNAIRE;

BIOSIMILAR PHARMACEUTICALS; CROHN DISEASE; EUROPE; GASTROINTESTINAL AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFLAMMATORY BOWEL DISEASES; SOCIETIES, MEDICAL; SURVEYS AND QUESTIONNAIRES;

EID: 85012283680     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw090     Document Type: Article

References (13)

1. European Medicines Agency. Inflectra. 2013. Available on http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/human_med_001677.jsp&mid=WC0b01ac058001d124, Accessed September 29, 2013.
2. European Medicines Agency. Remsima. 2013. Available on http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/human_med_001682.jsp&mid=WC0b01ac058001d124, Accessed September 29, 2013.
3. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallelgroup study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
4. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-12.
5. Gecse K, Farkas K, Lovasz BD, et al. Tu1348 biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort. Gastroenterology 2015;148:S-865-6.
6. Yoon S, Park D, Kim Y, Seo P, Kim K, Kang H. Efficacy and safety of infliximab's biosimilar (REMSIMA) for IBD. J Crohns Colitis 2015;9:S349-50.
7. Molnar T, Farkas K, Rutka M, et al. Efficacy of the new infliximab biomarker CT-P13 induction therapy on mucosal healing in ulcerative colitis patients. J Crohns Colitis 2015;9:S382.
8. U.S. National Institutes of Health. ClinicalTrials.gov. A randomized, double-blind, parallel-group study to evaluate the safety and efficacy of switching from innovator infliximab to biosimilar infliximab compared with continued treatment with innovator infliximab in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis: the NOR-SWITCH Study. 2015 https://clinicaltrials.gov/show/NCT02148640 Accessed October 12, 2015.
9. Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 2014;8:1548-50.
10. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-9.
11. Danese S, Gomollon F, Michetti P. EMA response to ECCO position statement on biosimilars. J Crohns Colitis 2014;8:259.
12. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I; SIR, SIDeMaST, and IG-IBD. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 2014;13:751-5.
13. Annese V, Vecchi M; Italian Group for the Study of IBD (IG-IBD). Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis 2014;46:963-8.